Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.9300 (-0.88%) ($7.7200 - $8.0200) on Mon. Jul. 15, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.78% (three month average) | RSI | 68 | Latest Price | $7.9300(-0.88%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.89% in a week (0% probabilities). VIXM(-39%) VXX(-38%) TLT(-9%) IFRA(-7%) UUP(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.89% (StdDev 3.78%) | Hourly BBV | 0 () | Intraday Trend | -1% | | | |
|
Resistance Level | $7.96 | 5 Day Moving Average | $8.05(-1.49%) | 10 Day Moving Average | $8.36(-5.14%) | 20 Day Moving Average | $7.96(-0.38%) | To recent high | -11.8% | To recent low | 26.5% | Market Cap | $1.004b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |